Next Generation Gynecological Cancer Diagnostics Market.pdf

1
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
res
https://www.freepik.com/premium-vector/dna-strand-molecular-structure-genetic-engineering-laboratory-research_4927901.htm
Focus on Technology, Product Type, End
User, and Country Analysis
Analysis and Forecast: 2020-2031
February 2022
Next-Generation
Gynecological Cancer
Diagnostics Market -
A Global Market and
Regional Analysis
Table of Content

2
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
BIS Research is a leading market intelligence and technology research company. BIS Research publishes in-
depth market intelligence reports focusing on the market estimations, technology analysis, emerging high-
growth applications, deeply segmented granular country-level market data and other important market
parameters useful in the strategic decision making for senior management. BIS Research provides multi-client
reports, company profiles, databases, and custom research services.
Copyright © 2022 BIS Research Inc.
All Rights Reserved. This document contains highly confidential information and is the sole property of BIS
Research. Disclosing, copying, circulating, quoting or otherwise reproducing any or all contents of this
document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people
or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third
party.

3
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Table of Content
1. Definition.................................................................................. 27
1.1 Inclusion and Exclusion Criteria ....................................................................27
1.1.1 Inclusions.....................................................................................................27
1.1.2 Exclusions ...................................................................................................27
2. Research Scope....................................................................... 28
2.1 Key Questions Answered in the Report ........................................................29
3. Research Methodology............................................................. 30
3.1 Global Next-Generation Gynecological Cancer Diagnostics Market:
Research Methodology ...................................................................................30
3.2 Data Sources....................................................................................................31
3.2.1 Primary Data Sources .................................................................................31
3.2.2 Secondary Data Sources ............................................................................32
3.3 Market Estimation Model.................................................................................32
3.4 Criteria for Company Profiling........................................................................34
4. Market...................................................................................... 35
4.1 Introduction......................................................................................................36
4.2 Molecular Profiling and Techniques ..............................................................37
4.3 Role of Molecular Diagnostics in Gynecological Cancers...........................39
4.4 Diagnostic Technologies and Regulatory Landmarks Timeline in
Gynecological Cancers ...................................................................................40
4.5 Emerging Molecular Testing in Gynecological Cancer ................................41
4.6 Current Market Size and Growth Potential, $Million, 2021-2031..................45
5. Role of Biomarkers in Gynecological Cancer............................. 47
5.1 Introduction......................................................................................................47
5.2 Predictive Molecular Testing in Gynecological Cancer ...............................48
5.3 Companion Diagnostics (CDx) .......................................................................49
6. COVID-19 Impact on Global Next-Generation Gynecological
Cancer Diagnostics Market ...................................................... 51
6.1 Impact on Supply Chain and Operations.......................................................51

4
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
6.2 COVID-19 Impact: Global Next-Generation Gynecological Cancer
Diagnostics Market..........................................................................................53
6.3 Pre- and Post-COVID-19 Impact Assessment ...............................................54
7. Market Dynamics...................................................................... 55
7.1 Overview...........................................................................................................55
7.2 Impact Analysis ...............................................................................................56
7.3 Market Drivers..................................................................................................56
7.3.1 Subsequent Decline in Next-Generation Sequencing (NGS) Cost..........56
7.3.2 Increased Recommendations from Government Organizations and
Scientific Societies......................................................................................57
7.3.3 Increased Awareness and Shift Toward Personalized Medicine.............57
7.4 Market Restraints.............................................................................................59
7.4.1 Limited Food and Drug Administration (FDA) Approved Next-
Generation Sequencing (NGS) tests..........................................................59
7.4.2 Complexities Involved with Overall Next-Generation Sequencing
(NGS) Process and Result Interpretation ..................................................59
7.4.3 Reimbursement Challenges Across the Countries ..................................61
7.5 Market Opportunities.......................................................................................61
7.5.1 Increased Market Investments and Government Funded Projects.........61
7.5.2 Next-Generation Sequencing (NGS) Acceptance by Emerging
Nations .........................................................................................................62
8. Industry Insights....................................................................... 63
8.1 Overview...........................................................................................................63
8.2 Legal Requirements and Framework in the U.S............................................63
8.2.1 FDA Regulation............................................................................................63
8.2.2 CMS Regulation...........................................................................................64
8.3 Legal Requirements and Framework in Europe............................................65
8.4 Legal Requirements and Framework in Asia-Pacific....................................66
8.4.1 China ............................................................................................................66
8.4.2 Japan............................................................................................................66
8.5 Reimbursement Scenario................................................................................67

5
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
8.6 Funding Scenario ............................................................................................70
9. Market Segmentation ............................................................... 71
9.1 Global Next-Generation Gynecological Cancer Diagnostics Market (by
Technology), $Million, 2020-2031...................................................................72
9.1.1 Overview ......................................................................................................72
9.1.1.1 Polymerase Chain Reaction (PCR) ..................................................................73
9.1.1.1.1 by Value ................................................................................................................... 73
9.1.1.1.2 by Volume ................................................................................................................ 74
9.1.1.2 Next-Generation Sequencing (NGS) ................................................................75
9.1.1.2.1 by Value ................................................................................................................... 76
9.1.1.2.2 by Volume ................................................................................................................ 76
9.1.1.2.3 Broad Panels............................................................................................................ 77
9.1.1.2.3.1 by Value............................................................................................................ 77
9.1.1.2.3.2 by Volume......................................................................................................... 78
9.1.1.2.4 Targeted Gene Panels............................................................................................. 79
9.1.1.2.4.1 by Value............................................................................................................ 79
9.1.1.2.4.2 by Volume......................................................................................................... 80
9.1.1.2.5 Single Gene Panels ................................................................................................. 80
9.1.1.2.5.1 by Value............................................................................................................ 80
9.1.1.2.5.2 by Volume......................................................................................................... 81
9.1.1.3 Other Technologies..........................................................................................82
9.1.1.3.1 by Value ................................................................................................................... 82
9.1.1.3.2 by Volume ................................................................................................................ 83
10. Global Next-Generation Gynecological Cancer Diagnostics
Market (by Product Type), $Million, 2020-2031.......................... 84
10.1 Overview...........................................................................................................84
10.2 Services............................................................................................................85
10.3 Products ...........................................................................................................86
Market (by Indication), $Million, 2020-2031 ............................... 88

6
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
11.1 Overview...........................................................................................................88
11.2 Ovarian Cancer ................................................................................................89
11.3 Cervical Cancer................................................................................................90
11.4 Uterine Cancer .................................................................................................91
Market (by End User), $Million, 2020-2031 ................................ 92
12.1 Overview...........................................................................................................92
12.2 Academic and Research Institutes ................................................................93
12.3 Hospitals and Ambulatory Centers................................................................94
12.4 Diagnostic Laboratories..................................................................................95
12.5 Other End Users ..............................................................................................96
Market (by Region), $Million, 2020-2031.................................... 97
13.1 Overview...........................................................................................................97
13.2 North America................................................................................................100
13.2.1 U.S. .............................................................................................................103
13.2.2 Canada .......................................................................................................104
13.3 Europe ............................................................................................................106
13.3.1 Germany.....................................................................................................109
13.3.2 U.K. .............................................................................................................110
13.3.3 France.........................................................................................................111
13.3.4 Italy .............................................................................................................112
13.3.5 Spain...........................................................................................................114
13.3.6 Netherlands................................................................................................115
13.3.7 Rest-of-Europe...........................................................................................116
13.4 Asia-Pacific ....................................................................................................117
13.4.1 China ..........................................................................................................119
13.4.2 Japan..........................................................................................................121
13.4.3 India............................................................................................................122
13.4.4 Australia.....................................................................................................123

7
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
13.4.5 South Korea ...............................................................................................124
13.4.6 Rest-of-Asia-Pacific...................................................................................125
13.5 Latin America.................................................................................................126
13.5.1 Brazil...........................................................................................................129
13.5.2 Mexico ........................................................................................................130
13.5.3 Rest-of-Latin America ...............................................................................131
13.6 Rest-of-the-World (RoW)...............................................................................132
14. Competitive Landscape and Company Profiles........................ 133
14.1 Competitive Landscape ................................................................................134
14.2 Regulatory and Legal Activities ...................................................................134
14.3 Synergistic Activities ....................................................................................135
14.4 Mergers and Acquisitions.............................................................................136
14.5 Product Launches .........................................................................................137
14.6 Business Expansions....................................................................................138
14.7 Market Share Analysis, by Service Providers, 2020 ...................................139
14.8 Market Share Analysis, by Product Manufacturers, 2020 ..........................141
14.9 Growth Share Analysis, by Company, 2019-2020.......................................142
14.9.1 Growth Share Analysis, by Service Providers, 2019-2020.....................142
14.9.2 Growth Share Analysis, by Product Manufacturers, 2019-2020............143
15. Company Profiles ................................................................... 145
15.1 Overview.........................................................................................................145
15.2 Agilent Technologies, Inc. ............................................................................146
15.2.1 Company Overview ...................................................................................146
15.2.2 Role of Agilent Technologies, Inc. in the Global Next-Generation
Gynecological Cancer Diagnostics Market .............................................146
15.2.3 Key Customers of the Company ..............................................................146
15.2.4 Key Competitors of the Company............................................................147
15.2.5 Financials...................................................................................................148
15.2.6 Key Insights About Financial Health of the Company ...........................150
15.2.7 Business Strategies ..................................................................................150

8
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
15.2.8 SWOT Analysis..........................................................................................151
15.3 ARUP Laboratories........................................................................................152
15.3.2 Role of ARUP Laboratories in the Global Next-generation
gynecological Cancer Diagnostics Market..............................................152
15.3.5 SWOT Analysis..........................................................................................154
15.4 BGI Genomics................................................................................................155
15.4.2 Role of BGI Genomics in the Global Next-Generation Gynecological
Cancer Diagnostics Market ......................................................................155
15.4.6 SWOT Analysis..........................................................................................157
15.5 CENTOGENE N.V...........................................................................................158
15.5.2 Role of CENTOGENE N.V. in the Global Next-Generation
15.5.5 Financials...................................................................................................160
15.5.7 SWOT Analysis..........................................................................................163
15.6 F. Hoffmann-La Roche Ltd............................................................................164
15.6.2 Role of F. Hoffmann-La Roche Ltd in the Global Next-Generation

9
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
15.6.5 Financials...................................................................................................166
15.6.8 SWOT Analysis..........................................................................................169
15.7 Fulgent Genetics, Inc. ...................................................................................170
15.7.4 Financials...................................................................................................172
15.7.7 SWOT Analysis..........................................................................................174
15.8 Illumina, Inc....................................................................................................175
15.8.2 Role of Illumina, Inc. in the Global Next-Generation Gynecological
15.8.5 Financials...................................................................................................177
15.8.7 SWOT Analysis..........................................................................................180
15.9 Invitae Corporation........................................................................................181
15.9.2 Role of Invitae Corporation in the Global Next-Generation
15.9.5 Financials...................................................................................................183

10
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
15.9.8 SWOT Analysis..........................................................................................186
15.10 Konica Minolta, Inc........................................................................................187
15.10.1 Company Overview.............................................................................187
15.10.2 Role of Konica Minolta, Inc. in the Global Next-Generation
15.10.3 Key Customers of the Company........................................................187
15.10.4 Key Competitors of the Company .....................................................188
15.10.5 Financials ............................................................................................189
15.10.6 Key Insights About Financial Health of the Company.....................191
15.10.7 Business Strategies............................................................................191
15.10.8 SWOT Analysis....................................................................................192
15.11 Laboratory Corporation of America Holdings.............................................193
15.11.2 Role of Laboratory Corporation of America Holdings in the
Global Next-Generation Gynecological Cancer Diagnostics Market ....193
15.11.5 Financials ............................................................................................195
15.11.7 SWOT Analysis....................................................................................197
15.12 Myriad Genetics, Inc......................................................................................198
15.12.2 Role of Myriad Genetics, Inc. in the Global Next-Generation
15.12.5 Financials ............................................................................................200
15.12.6 SWOT Analysis....................................................................................201
15.13 OPKO Health, Inc...........................................................................................202

11
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
15.13.2 Role of OPKO Health, Inc. in the Global Next-Generation
15.13.5 Financials ............................................................................................204
15.13.7 SWOT Analysis....................................................................................207
15.14 QIAGEN N.V....................................................................................................208
15.14.2 Role of QIAGEN N.V. in the Global Next-Generation
15.14.5 Financials ............................................................................................210
15.14.8 SWOT Analysis....................................................................................213
15.15 Quest Diagnostics Incorporated ..................................................................214
15.15.2 Role of Quest Diagnostics Incorporated in the Global Next-
Generation Gynecological Cancer Diagnostics Market .........................214
15.15.5 Financials ............................................................................................216
15.15.6 SWOT Analysis....................................................................................217
15.16 Thermo Fisher Scientific Inc.........................................................................218
15.16.2 Role of Thermo Fisher Scientific Inc. in the Global Next-
Generation Gynecological Cancer Diagnostics Market .........................218

12
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
15.16.5 Financials ............................................................................................220
15.16.7 SWOT Analysis....................................................................................223
Emerging companies .................................................................... 224
15.17 Overview.........................................................................................................224
15.18 NgeneBio........................................................................................................224
15.18.2 Role of NgeneBio in the Global Next-Generation Gynecological
15.19 oncgnostics GmbH........................................................................................225
15.19.2 Role of oncgnostics GmbH in the Global Next-Generation
15.20 Self-screen B.V. .............................................................................................226
15.20.2 Role of Self-screen B.V. in the Global Next-Generation
15.21 Strata Oncology, Inc......................................................................................227
15.21.2 Role of Strata Oncology, Inc. in the Global Next-Generation

13
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
List of Figures
Figure 1: Impact Analysis of Market Drivers and Opportunities in Global Next-Generation Gynecological
Cancer Diagnostics Market
Figure 2: Global Next-Generation Gynecological Cancer Diagnostics Market (by Technology), 2020 and
2031
Figure 3: Global Next-Generation Gynecological Cancer Diagnostics Market (by Product Type), 2020
and 2031
Figure 4: Global Next-Generation Gynecological Cancer Diagnostics Market (by Indication), 2020 and
2031
Figure 5: Global Next-Generation Gynecological Cancer Diagnostics Market (by End User), 2020 and
2031
Figure 6: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region), 2020-2031
Figure 7: Global Next-Generation Gynecological Cancer Diagnostics Market Segmentation
Figure 8: Figure: Global Next-Generation Gynecological Cancer Diagnostics Market: Methodology
Figure 9: Figure: Bottom-Up Approach (Segment-Wise Analysis)
Figure 10: Figure: Top-Down Approach (Segment-Wise Analysis)
Figure 11: Cervical Cancer, Incidence Cases and New Cases (2008-2018)
Figure 12: Ovarian Cancer, Incidence Cases and New Cases (2008-2018)
Figure 13: Molecular Diagnostics Evolution Timeline
Figure 14: Types of Molecular Diagnostics Technologies
Figure 15: Diagnostic Technologies and Regulatory Landmark Timeline
Figure 16: Type of Non-Invasive Next Generation Novel Molecular Diagnostics
Figure 17: Evolution of Sequencing Technologies
Figure 18: Difference Between Polymerase Chain reaction (PCR) Across Three Generation Sequencing
Figure 19: Global Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 20: Potential Biomarkers for Gynecological Cancer Detection
Figure 21: Number of Food and Drug Administration (FDA) Approved Companion Diagnostics (CDx),
(1998–2020)
Figure 22: Number of Food and Drug Administration (FDA) Approved Companion Diagnostics (CDx)
Assays by Analytical Platform/Technology
Figure 23: Laboratory Setting and Testing Methodologies Being Adopted by the Respondent’s
Laboratories
Figure 24: Types of Molecular Testing for Cancer Performed

14
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Figure 25: Global Next-Generation Gynecological Cancer Diagnostics Market: COVID-19 Impact
Figure 26: Impact of COVID-19 on Global Next-Generation Gynecological Cancer Diagnostics Market
Figure 27: Global Next-Generation Gynecological Cancer Diagnostics, Market Dynamics
Figure 28: Impact Analysis of Market Drivers and Opportunities on Global Next-Generation
Gynecological Cancer Diagnostics Market
Figure 29: Cost per Human Genome (2014–2021)
Figure 30: Approved Number of Personalized Medicine (2016–2020)
Figure 31: Percentage of Food and Drug Administration (FDA) Approved Personalized Medicines (2015–
2020)
Figure 32: Next-Generation Sequencing (NGS) for Human Papillomavirus (HPV) Detection and
Characterization Process Steps
Figure 33: Global Next-Generation Gynecological Cancer Diagnostics Market (by Technology), 2020 and
2031
Figure 34: Global Next-Generation Gynecological Cancer Diagnostics Market (Polymerase Chain
Reaction (PCR)), $Million, 2020-2031
Figure 35: Global Next-Generation Gynecological Cancer Diagnostics Market (Polymerase Chain
Reaction (PCR)), Thousand Units, 2020-2031
Figure 36: Global Next-Generation Gynecological Cancer Diagnostics Market (Next-Generation
Sequencing (NGS)), $Million, 2020-2031
Figure 37: Global Next-Generation Gynecological Cancer Diagnostics Market (Next-Generation
Sequencing (NGS)), Thousand Units, 2020-2031
Figure 38: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation
Sequencing (NGS), Broad Panels), $Million, 2020-2031
Sequencing (NGS), Broad Panels), Thousand Units, 2020-2031
Sequencing (NGS), Targeted Gene Panels), $Million, 2020-2031
Sequencing (NGS), Targeted Gene Panels), Thousand Units, 2020-2031
Sequencing (NGS), Single Gene Panels), $Million, 2020-2031
Sequencing (NGS), Single Gene Panels), Thousand Units, 2020-2031
Figure 44: Global Next-Generation Gynecological Cancer Diagnostics Market (Other Technologies),
$Million, 2020-2031

15
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Figure 45: Global Next-Generation Gynecological Cancer Diagnostics Market (Other Technologies),
Thousand Units, 2020-2031
Figure 46: Global Next-Generation Gynecological Cancer Diagnostics Market (by Product Type), 2020
and 2031
Figure 47: Global Next-Generation Gynecological Cancer Diagnostics Market (Services), $Million, 2020-
2031
Figure 48: Global Next-Generation Gynecological Cancer Diagnostics Market (Products), $Million, 2020-
2031
Figure 49: Global Next-Generation Gynecological Cancer Diagnostics Market (by Indication), 2020 and
2031
Figure 50: Global Next-Generation Gynecological Cancer Diagnostics Market (Ovarian Cancer), $Million,
2020-2031
Figure 51: Global Next-Generation Gynecological Cancer Diagnostics Market (Cervical Cancer), $Million,
2020-2031
Figure 52: Global Next-Generation Gynecological Cancer Diagnostics Market (Uterine Cancer), $Million,
2020-2031
Figure 53: Global Next-Generation Gynecological Cancer Diagnostics Market (by End User), 2020 and
2031
Figure 54: Global Next-Generation Gynecological Cancer Diagnostics Market (Academic and Research
Institutes), $Million, 2020-2031
Figure 55: Global Next-Generation Gynecological Cancer Diagnostics Market (Hospitals and Ambulatory
Centers), $Million, 2020-2031
Figure 56: Global Next-Generation Gynecological Cancer Diagnostics Market (Diagnostic Laboratories),
$Million, 2020-2031
Figure 57: Global Next-Generation Gynecological Cancer Diagnostics Market (Other End Users),
$Million, 2020-2031
Figure 58: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region)
Figure 59: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region), 2020-2031
Figure 60: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region), $Million,
2020-2031
Figure 61: North America Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-
2031
Figure 62: North America, Market Dynamics
Figure 63: North America Next-Generation Gynecological Cancer Diagnostics Market (by Country),
2020-2031

16
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Figure 64: U.S. Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 65: Canada Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 66: Europe Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 67: Europe, Market Dynamics
Figure 68: Europe Next-Generation Gynecological Cancer Diagnostics Market (by Country), 2020-2031
Figure 69: Germany Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 70: U.K. Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 71: France Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 72: Italy Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 73: Spain Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 74: Netherlands Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 75: Rest-of-Europe Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-
2031
Figure 76: Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 77: APAC, Market Dynamics
Figure 78: APAC Next-Generation Gynecological Market (by Country), 2020-2031
Figure 79: China Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 80: Japan Next-Generation Cancer Gynecological Cancer Diagnostics Market, $Million, 2020-
2031
Figure 81: India Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 82: Australia Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 83: South Korea Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 84: RoAPAC Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 85: Latin America Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-
2031
Figure 86: Latin America, Market Dynamics
Figure 87: Latin America Next-Generation Gynecological Cancer Diagnostics Market (by Country), 2020-
2031
Figure 88: Brazil Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 89: Mexico Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
Figure 90: Rest-of-Latin America Next-Generation Gynecological Cancer Diagnostics Market, $Million,
2020-2031
Figure 91: RoW Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031

17
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Figure 92: Share of Key Developments and Strategies, January 2019–January 2022
Figure 93: Share of Regulatory and Legal Activities (by Company), January 2019–January 2022
Figure 94: Share of Synergistic Activities (by Company), January 2019–January 2022
Figure 95: Share of Mergers and Acquisitions (by Company), January 2019–January 2022
Figure 96: Share of Product Launches (by Company), January 2019–January 2022
Figure 97: Share of Business Expansions (by Company), January 2019–January 2022
Figure 98: Market Share Analysis for Global Next-Generation Gynecological Cancer Diagnostics Market
(by Service Providers), 2020
Figure 99: Market Share Analysis for Global Next-Generation Gynecological Cancer Diagnostics Market
(by Manufacturers), 2020
Figure 100: Growth Share Analysis for Global next-generation gynecological cancer diagnostics, (by
Service Providers), 2020
Figure 101: Growth Share Analysis for Global next-generation gynecological cancer diagnostics, (by
Product Manufacturers), 2020
Figure 102: Shares of Key Company Profiles
Figure 103: Agilent Technologies, Inc.: Product Portfolio
Figure 104: Agilent Technologies, Inc.: Overall Financials/Revenue, $Million, 2019-2021
Figure 105: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 106: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 107: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 108: Agilent Technologies, Inc.: SWOT Analysis
Figure 109: ARUP Laboratories: Service Portfolio
Figure 110: ARUP Laboratories: SWOT Analysis
Figure 111: BGI Genomics: Product Portfolio
Figure 112: BGI Genomics: SWOT Analysis
Figure 113: CENTOGENE N.V.: Service Portfolio
Figure 114: CENTOGENE N.V.: Overall Financials/Revenue, $Million, 2018-2020
Figure 115: CENTOGENE N.V.: Revenue (by Business Segment), $Million, 2018-2020
Figure 116: CENTOGENE N.V.: Revenue (by Region), $Million, 2018-2020
Figure 117: CENTOGENE N.V.: R&D Expenditure, $Million, 2018-2020
Figure 118: CENTOGENE N.V.: SWOT Analysis
Figure 119: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 120: F. Hoffmann-La Roche Ltd: Overall Financials/Revenue, $Billion, 2019-2021

18
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Figure 121: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Billion, 2019-2021
Figure 122: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Billion, 2019-2021
Figure 123: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Billion, 2019-2021
Figure 124: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 125: Fulgent Genetics, Inc.: Service Portfolio
Figure 126: Fulgent Genetics, Inc.: Overall Financials/Revenue, $Million, 2018-2020
Figure 127: Fulgent Genetics, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 128: Fulgent Genetics, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 129: Fulgent Genetics, Inc.: SWOT Analysis
Figure 130: Illumina, Inc.: Product Portfolio
Figure 131: Illumina, Inc.: Overall Financials/Revenue, $Million, 2018-2020
Figure 132: Illumina, Inc.: Revenue (by Business Segment), $Million, 2018–2020
Figure 133: Illumina, Inc.: Revenue (by Region), $Million, 2018–2020
Figure 134: Illumina, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 135: Illumina, Inc.: SWOT Analysis
Figure 136: Invitae Corporation: Service Portfolio
Figure 137: Invitae Corporation: Overall Financials/Revenue, $Million, 2018-2020
Figure 138: Invitae Corporation: Revenue (by Business Segment), $Million, 2018–2020
Figure 139: Invitae Corporation: Revenue (by Region), $Million, 2018-2020
Figure 140: Invitae Corporation: R&D Expenditure, $Million, 2018-2020
Figure 141: Invitae Corporation: SWOT Analysis
Figure 142: Konica Minolta, Inc.: Service Portfolio
Figure 143: Konica Minolta, Inc.: Overall Financials/Revenue, $Million, 2018-2020
Figure 144: Konica Minolta, Inc.: Revenue (by Business Segment), $Million, 2019-2020
Figure 145: Konica Minolta, Inc.: Revenue (by Healthcare Business), $Million, 2019-2020
Figure 146: Konica Minolta, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 147: Konica Minolta, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 148: Konica Minolta, Inc.: SWOT Analysis
Figure 149: Laboratory Corporation of America Holdings: Service Portfolio
Figure 150: Laboratory Corporation of America Holdings: Overall Financials/Revenue, $Million, 2018-2020
Figure 151: Laboratory Corporation of America Holdings: Revenue (by Segment), $Million, 2018-2020
Figure 152: Laboratory Corporation of America Holdings: Revenue (by Region), $Million, 2018-2020
Figure 153: Laboratory Corporation of America Holdings: SWOT Analysis

19
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Figure 154: Myriad Genetics, Inc.: Service Portfolio
Figure 155: Myriad Genetics, Inc.: Overall Financials/Revenue, 2018-2020
Figure 156: Myriad Genetics, Inc.: Revenue (by Business Segment), 2018-2020
Figure 157: Myriad Genetics, Inc.: SWOT Analysis
Figure 158: OPKO Health, Inc.: Service Portfolio
Figure 159: OPKO Health, Inc.: Overall Financials/Revenue, $Million, 2018-2020
Figure 160: OPKO Health, Inc.: Revenue (by Business Segment), $Million, 2018–2020
Figure 161: OPKO Health, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 162: OPKO Health, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 163: OPKO Health: SWOT Analysis
Figure 164: QIAGEN N.V.: Product Portfolio
Figure 165: QIAGEN N.V.: Overall Financials/Revenue, 2019-2021
Figure 166: QIAGEN N.V.: Revenue (by Segment), 2019-2021
Figure 167: QIAGEN N.V.: Revenue (by Region), 2019-2021
Figure 168: QIAGEN N.V.: R&D Expenditure, 2019-2021
Figure 169: QIAGEN N.V.: SWOT Analysis
Figure 170: Quest Diagnostics Incorporated: Service Portfolio
Figure 171: Quest Diagnostics Incorporated: Overall Financials/Revenue, $Million, 2018-2020
Figure 172: Quest Diagnostics Incorporated: Revenue (by Business Segment), $Million, 2018-2020
Figure 173: Quest Diagnostics Incorporated: SWOT Analysis
Figure 174: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 175: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2018-2020
Figure 176: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), $Million, 2018–2020
Figure 177: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2018–2020
Figure 178: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2018-2020
Figure 179: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 180: NgeneBio: Product Portfolio
Figure 181: oncgnostics GmbH: Product Portfolio
Figure 182: Self-screen B.V.: Product Portfolio
Figure 183: Strata Oncology, Inc.: Product Portfolio

20
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
List of Tables
Table 1: Risks Associated with the Types of Genes Related to Hereditary Ovarian and Uterine Cancer
Table 2: Advantages and Limitations of Short-Read Sequencing and Long-Read Sequencing
Table 3: National Comprehensive Cancer Network (NCCN) Recommended Predictive Molecular
Testing in Gynecological Cancer
Table 4: Food and Drug Administration (FDA) Approved Companion Diagnostics (CDx) for
Gynecological Cancers
Table 5: Reimbursement Scenario Across Major Countries
Table 6: Regulatory Framework and Reimbursement Options of NGS-Based Diagnostics Across Major
Countries
Table 7: Next-Generation Sequencing Clinical Utility in Gynecological Cancers
Table 8: Services Offered by Key Players
Table 9: Products Offered by Key Players

21
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s
digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions
worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other
innovative solutions.
Know More Know More
Know More
Know More

22
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to
orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth.
This document and its contents are confidential and may not be further distributed, published or reproduced,
in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS
Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly
through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information
to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce
Information in legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information is
available. Any recommendation contained in this report may not be suitable for all investors or businesses.
The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to
market fluctuations and business, economic and competitive uncertainties, and contingencies
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135

23
G
L
O
B
A
L
N
E
X
T
-
G
E
N
E
R
A
T
I
O
N
G
Y
N
E
C
O
L
O
G
I
C
A
L
C
A
N
C
E
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
www.bisresearch.com

Next Generation Gynecological Cancer Diagnostics Market.pdf

Recommended

Recommended

More Related Content

Similar to Next Generation Gynecological Cancer Diagnostics Market.pdf

Similar to Next Generation Gynecological Cancer Diagnostics Market.pdf (20)

More from BIS Research Inc.

More from BIS Research Inc. (20)

Recently uploaded

Recently uploaded (20)

Next Generation Gynecological Cancer Diagnostics Market.pdf